Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026)

Regeneron Pharmaceuticals' Long-Term Deferred Tax history runs 16 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 21.73% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 21.73% YoY), while the FY2025 annual figure was $4.1 billion, up 23.03% from the prior year.
• Long-Term Deferred Tax was $4.2 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $4.1 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $4.2 billion in Q1 2026 to a low of $1.1 billion in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $2.7 billion across 5 years, with a median of $2.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax jumped 100.79% in 2022, then advanced 21.73% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.7 billion in 2022, then surged by 49.41% to $2.6 billion in 2023, then gained by 28.68% to $3.3 billion in 2024, then rose by 23.03% to $4.1 billion in 2025, then gained by 2.79% to $4.2 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $4.2 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.